New oral drug INT-210 aims to tame ulcerative colitis Flare-Ups
Disease control
Recruiting now
This study tests an experimental oral drug called INT-210 in adults with active ulcerative colitis, a chronic inflammatory bowel disease. Participants take either 200 mg or 400 mg of INT-210 twice daily for 12 weeks. The main goals are to check the drug's safety and how the body …
Phase: PHASE1, PHASE2 • Sponsor: Innatus Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC